AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12714403 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscocanalostomy with reticulated hyaluronic acid implant (VSRHAI)
Number of subjects: 40
Study 10886700 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 32
Study 10886700 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 32
Study 7486361 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP (n = 60)
Number of subjects: 100
Study 7486361 — intervention group
Group type: COMPARATOR
Intervention: SVN (n = 40)
Number of subjects: 100
Study 2366020 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and positional views of normal wrists under stress
Number of subjects: 53
Study 2366020 — intervention group
Group type: COMPARATOR
Intervention: Injured wrists with pathological roentgenographic appearances
Number of subjects: 53
Study 36422 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 0
Study 36422 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 0
Study 36422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31774408 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot (Vik)
Number of subjects: 142
Study 31774408 — intervention group
Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 142
Study 28610884 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical AVR
Number of subjects: 2138
Study 26999924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.003 mg/kg)
Number of subjects: 46
Study 26999924 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intrathecal morphine)
Number of subjects: 46
Study 23827330 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium nitrate (NaNO3)
Number of subjects: 20
Study 23827330 — intervention group
Group type: COMPARATOR
Intervention: sodium chloride (NaCl) (saline placebo)
Number of subjects: 20
Study 21801403 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 108 (300 mg SC)
Number of subjects: 160
Study 21801403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 18329883 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing (FB) total knee arthroplasty
Number of subjects: 102
Study 18329883 — intervention group
Group type: COMPARATOR
Intervention: Mobile-bearing (MB) total knee arthroplasty
Number of subjects: 102
Study 16520527 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of public benefits, health insurance coverage, moderate social support, avoidance of illegal activity, HIV seropositivity
Number of subjects: 511
Study 16520527 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of public benefits, hospitalization, primary care, avoiding re-arrest
Number of subjects: 511
Study 16520527 — intervention group
Group type: COMPARATOR
Intervention: Chronic diseases (diabetes, asthma, depression)
Number of subjects: 511
Study 12828691 — intervention group
Group type: EXPERIMENTAL
Intervention: Four single-pass treatments at 2-week intervals
Number of subjects: 20
Study 12828691 — intervention group
Group type: EXPERIMENTAL
Intervention: Four double-pass treatments at 2-week intervals
Number of subjects: 20
Study 12828691 — intervention group
Group type: COMPARATOR
Intervention: Both treatment methods (single-pass and double-pass)
Number of subjects: 20
Study 10853619 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 10 mg/kg (as caffeine base) administered intravenously, followed by 2.5 mg/kg/day orally or intravenously, for up to 10 days.
Number of subjects: 85
Study 10853619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 9394698 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber diet (LFHFD)
Number of subjects: 31
Study 9394698 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, low-fiber diet (LFLFD)
Number of subjects: 31
Study 8497683 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO‐1078 (225 mg twice a day)
Number of subjects: 11
Study 8497683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2448863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CDDP‐5 FU
Number of subjects: 135
Study 2448863 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP‐BLM‐VCR‐MTX
Number of subjects: 135
Study 2448863 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP‐BLM‐VDS
Number of subjects: 135
Study 2448863 — intervention group
Group type: EXPERIMENTAL
Intervention: Small tumors (T1, T2)
Number of subjects: 135
Study 29275502 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-gauge needle
Number of subjects: 88
Study 29275502 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-gauge needle
Number of subjects: 88
Study 25539597 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete CYD final report
Number of subjects: 741
Study 25539597 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback components of the CYD
Number of subjects: 741
Study 25539597 — intervention group
Group type: COMPARATOR
Intervention: Normative feedback components of the CYD
Number of subjects: 741
Study 25539597 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 741
Study 22859357 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 50 mg bid
Number of subjects: 400
Study 22859357 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 800/400 mg
Number of subjects: 400
Study 22859357 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg tid
Number of subjects: 400
Study 20159250 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 13542
Study 20159250 — intervention group
Group type: COMPARATOR
Intervention: Non-LABA
Number of subjects: 13542
Study 18672985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge-preservation procedure with corticocancellous porcine bone and collagen membrane
Number of subjects: 40
Study 18672985 — intervention group
Group type: COMPARATOR
Intervention: Extraction alone
Number of subjects: 40
Study 15877867 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato juice (330 ml/d, 37.0 mg lycopene, 1.6 mg beta-carotene) for 2 weeks
Number of subjects: 22
Study 15877867 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrot juice (330 ml/d, 27.1 mg beta-carotene, 13.1 mg alpha-carotene) for 2 weeks
Number of subjects: 22
Study 15877867 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison of lag time
Number of subjects: 22
Study 12929855 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin-treated mosquito nets, mosquito repellent cream, and weekly chemoprophylaxis with 300 mg chloroquine
Number of subjects: 0
Study 12929855 — intervention group
Group type: COMPARATOR
Intervention: Control measures prior to intervention
Number of subjects: 0
Study 10391671 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg rofecoxib
Number of subjects: 94
Study 10391671 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib
Number of subjects: 94
Study 10391671 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 94
Study 10391671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 8730609 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil (RO) diet
Number of subjects: 40
Study 8730609 — intervention group
Group type: COMPARATOR
Intervention: Trisun-sunflower oil (TSO) diet
Number of subjects: 40
Study 1486963 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (24 mg)
Number of subjects: 12
Study 1486963 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg)
Number of subjects: 12
Study 1486963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4037215 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic (Droperidol)
Number of subjects: 58
Study 4037215 — intervention group
Group type: COMPARATOR
Intervention: No neuroleptic (Control group)
Number of subjects: 58
Study 30895893 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive image appeal with low descriptive norm
Number of subjects: 204
Study 30895893 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative image appeal with low descriptive norm
Number of subjects: 204
Study 30895893 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive image appeal with high descriptive norm
Number of subjects: 204
Study 30895893 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative image appeal with high descriptive norm
Number of subjects: 204
Study 29320549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular botulinum toxin A (30 IU)
Number of subjects: 6
Study 29320549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 27011305 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 72
Study 27011305 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression
Number of subjects: 72
Study 27011305 — intervention group
Group type: COMPARATOR
Intervention: Supine Rest
Number of subjects: 72
Study 24667502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection-based training using laparoscopic dissection models
Number of subjects: 46
Study 24667502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection-based laparoscopic training
Number of subjects: 46
Study 24667502 — intervention group
Group type: COMPARATOR
Intervention: Lectures only (Group I)
Number of subjects: 46
Study 24667502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lectures and dissection-based laparoscopic training (Group III)
Number of subjects: 46
Study 20447533 — intervention group
Group type: EXPERIMENTAL
Intervention: Global thrombosis test (GTT) assessing lysis time (LT)
Number of subjects: 300
Study 20447533 — intervention group
Group type: EXPERIMENTAL
Intervention: Global thrombosis test (GTT) assessing occlusion time (OT)
Number of subjects: 300
Study 18843939 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 18843939 — intervention group
Group type: COMPARATOR
Intervention: Placebo or typical/atypical antipsychotics
Number of subjects: 0
Study 15889606 — intervention group
Group type: EXPERIMENTAL
Intervention: Paula Garburg sphincter muscle exercises combined with Young vaginal dilators
Number of subjects: 60
Study 15889606 — intervention group
Group type: COMPARATOR
Intervention: Masters and Johnson's desensitization approach combined with Young vaginal dilators
Number of subjects: 60
Study 12638308 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen deficiency
Number of subjects: 0
Study 12638308 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 0
Study 12638308 — intervention group
Group type: COMPARATOR
Intervention: Guidelines for hypertension management
Number of subjects: 0
Study 10574854 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% glucose
Number of subjects: 150
Study 10574854 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sucrose
Number of subjects: 150
Study 10574854 — intervention group
Group type: EXPERIMENTAL
Intervention: pacifier
Number of subjects: 150
Study 10574854 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% sucrose plus pacifier
Number of subjects: 150
Study 10574854 — intervention group
Group type: COMPARATOR
Intervention: placebo (sterile water)
Number of subjects: 150
Study 10574854 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 150
Study 8933994 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Number of subjects: 20
Study 8933994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1806622 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan (100 mg)
Number of subjects: 12
Study 1806622 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg)
Number of subjects: 12
Study 1806622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7063809 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting
Number of subjects: 5
Study 7063809 — intervention group
Group type: COMPARATOR
Intervention: Lactovegetarian diet
Number of subjects: 5
Study 31451854 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin nasal spray
Number of subjects: 30
Study 31451854 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 30
Study 28013329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate (NMBA) continuous infusion for 48 hours in moderate ARDS patients
Number of subjects: 30
Study 28013329 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NMBA) in moderate ARDS patients
Number of subjects: 30
Study 28013329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium besylate (NMBA) for severe ARDS patients (no randomization)
Number of subjects: 30
Study 28013329 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving pressure and delta P L (∆P L) related to NMBA administration
Number of subjects: 30
Study 26505132 — intervention group
Group type: EXPERIMENTAL
Intervention: e.max CAD (Cerec AC system)
Number of subjects: 40
Study 26505132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cercon (zirconia-based)
Number of subjects: 40
Study 26505132 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS e.max Press
Number of subjects: 40
Study 26505132 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-ceramic restorations
Number of subjects: 40
Study 24600657 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine bone mineral plus collagen membrane (test)
Number of subjects: 48
Study 24600657 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (control)
Number of subjects: 48
Study 23018283 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine suspension (50 mg/mL)
Number of subjects: 0
Study 23018283 — intervention group
Group type: COMPARATOR
Intervention: Clozaril(®) tablets
Number of subjects: 0
Study 23018283 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine suspension and Clozaril(®) tablets
Number of subjects: 0
Study 20472916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 156
Study 20472916 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 156
Study 20472916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 18238728 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial falls-prevention program (Stand Up!)
Number of subjects: 10
Study 16227551 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI brain scan
Number of subjects: 150
Study 16227551 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 150
Study 12085247 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (communication skills training workshop)
Number of subjects: 115
Study 12085247 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 115
Study 9928544 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/hormone replacement therapy (ERT/HRT)
Number of subjects: 0
Study 8585289 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent liposome‐adjuvanted vaccine
Number of subjects: 77
Study 8585289 — intervention group
Group type: COMPARATOR
Intervention: Control subvirion vaccine
Number of subjects: 77
Study 8585289 — intervention group
Group type: EXPERIMENTAL
Intervention: Licensed trivalent subvirion vaccine (reimmunization after 18 weeks)
Number of subjects: 77
Study 8585289 — intervention group
Group type: COMPARATOR
Intervention: Young adults (control group for comparison)
Number of subjects: 77
Study 2816237 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 6 mg/kg as a rapid intravenous bolus during CPB
Number of subjects: 30
Study 2816237 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone 6 mg/kg as a 15‐min intravenous infusion before CPB
Number of subjects: 30
Study 2816237 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro binding of thiopentone to CPB equipment
Number of subjects: 30
Study 29293362 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-In (OI) technique
Number of subjects: 128
Study 29293362 — intervention group
Group type: COMPARATOR
Intervention: Transportal (TP) technique
Number of subjects: 128
Study 29293362 — intervention group
Group type: EXPERIMENTAL
Intervention: KT-2000 arthrometer results
Number of subjects: 128
Study 29293362 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look arthroscopic findings
Number of subjects: 128
Study 29293362 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 128
Study 28969611 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention consisting of 10 modules tailored to treatment type, relationship status, and sexual orientation.
Number of subjects: 140
Study 28969611 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 140
Study 28969611 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study 26309217 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin 2 (Ang2) plasma levels
Number of subjects: 21
Study 26309217 — intervention group
Group type: EXPERIMENTAL
Intervention: sTie2 plasma levels
Number of subjects: 21
Study 26309217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang1 plasma levels
Number of subjects: 21
Study 26309217 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary levels of N-acetyl-beta-D-glucosaminidase (NAG)
Number of subjects: 21
Study 23312680 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 50
Study 23312680 — intervention group
Group type: COMPARATOR
Intervention: Bedding pillow
Number of subjects: 50
Study 22003405 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon (PEG) and weight-based ribavirin (WBR) therapy
Number of subjects: 231
Study 22003405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment prediction score incorporating IL28B genotype and baseline HCV viral load
Number of subjects: 231
Study 18352915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlets (P)
Number of subjects: 3
Study 18352915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlets + Lecture (P + L)
Number of subjects: 3
Study 18352915 — intervention group
Group type: COMPARATOR
Intervention: No intervention/control (C)
Number of subjects: 3
Study 17075906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy combined with cognitive behavioral therapy (CBT)
Number of subjects: 0
Study 17075906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological agents
Number of subjects: 0
Study 12846865 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 40
Study 12846865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg/day
Number of subjects: 40
Study 12846865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10915231 — intervention group
Group type: EXPERIMENTAL
Intervention: Office blood pressure measurement
Number of subjects: 21
Study 10915231 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory blood pressure measurement
Number of subjects: 21
Study 10915231 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring blood pressure measurement
Number of subjects: 21
Study 10915231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillometric wrist device
Number of subjects: 21
Study 8986200 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 35
Study 8986200 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study 1456575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 95
Study 1456575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 1456575 — intervention group
Group type: COMPARATOR
Intervention: Canister weight measurement
Number of subjects: 95
Study 1456575 — intervention group
Group type: COMPARATOR
Intervention: Self-report
Number of subjects: 95
Study 1456575 — intervention group
Group type: COMPARATOR
Intervention: Microprocessor monitoring (Nebulizer Chronolog)
Number of subjects: 95
Study 6741668 — intervention group
Group type: EXPERIMENTAL
Intervention: High maintenance doses of methadone (Group 1) for a 14-week period
Number of subjects: 0
Study 6741668 — intervention group
Group type: COMPARATOR
Intervention: No dose modifications (Group 2) during the same 14-week period
Number of subjects: 0
Study 31013172 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 42
Study 31013172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 29754952 — intervention group
Group type: EXPERIMENTAL
Intervention: Early time-restricted feeding (eTRF) - 6-hour feeding period, dinner before 3 p.m.
Number of subjects: 0
Study 29754952 — intervention group
Group type: COMPARATOR
Intervention: Control schedule - 12-hour feeding period
Number of subjects: 0
Study 27117285 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 93
Study 27117285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 25365892 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural low-dose morphine-soaked microfibrillar collagen sponge (MMCS)
Number of subjects: 0
Study 25365892 — intervention group
Group type: COMPARATOR
Intervention: Epidural normal saline-soaked microfibrillar collagen sponge (placebo)
Number of subjects: 0
Study 22812450 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI measurements of the musculoskeletal system, brain and pain perception, cardiovascular system, body composition, oxidative stress and inflammation.
Number of subjects: 44
Study 22812450 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily urine samples, periodic blood samples, and electrocardiograms (ECG).
Number of subjects: 44
Study 22812450 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) and anthropological measurements.
Number of subjects: 44
Study 22812450 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological questionnaires.
Number of subjects: 44
Study 22812450 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall race performance metrics.
Number of subjects: 44
Study 19570764 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with potassium canrenoate (200 mg/day, increased to 400 mg/day) and furosemide (50 mg/day, increased to 150 mg/day)
Number of subjects: 100